We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3ß, a master regulator of complex biological signaling cascades, including those mediated by oncogenes,that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade GSK-3ß signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity
Lead Underwriter
Titan Partners Group LLC, a division of American Capital Part...
